{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:55:21Z","timestamp":1789206921288,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.rdc.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T21:27:41Z","timestamp":1542230861000},"page":"145-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Challenges of Approaching and Managing Gout"],"prefix":"10.1016","volume":"45","author":[{"given":"Theodore R.","family":"Fields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rdc.2018.09.009_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semarthrit.2015.02.004","article-title":"The economic burden of gout: a systematic review","volume":"45","author":"Rai","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10067-015-3039-2","article-title":"\"You want to get on with the rest of your life\": a qualitative study of health-related quality of life in gout","volume":"35","author":"Chandratre","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/erp.12.60","article-title":"The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension","volume":"12","author":"DiBonaventura","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.rdc.2018.09.009_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib6","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2016.3517","article-title":"Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011","volume":"315","author":"Lim","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.rdc.2018.09.009_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","article-title":"The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years","volume":"45","author":"Elfishawi","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.22469","article-title":"Gout, urate-lowering therapy, and uric acid levels among adults in the United States","volume":"67","author":"Juraschek","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2018.09.009_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.rdc.2018.09.009_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2474-13-180","article-title":"Patients' knowledge and beliefs concerning gout and its treatment: a population based study","volume":"13","author":"Harrold","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.rdc.2018.09.009_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.140588","article-title":"Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system","volume":"42","author":"Rashid","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2018.09.009_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2018.09.009_bib16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British Society for Rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2018.09.009_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.semarthrit.2016.10.006","article-title":"Pilot study of a multidisciplinary gout patient education and monitoring program","volume":"46","author":"Fields","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/acr.22879","article-title":"\"You don't have to be a drinker to get gout, but it helps\": a content analysis of the depiction of gout in popular newspapers","volume":"68","author":"Duyck","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2018.09.009_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.rdc.2018.09.009_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A\u00a0retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2018.09.009_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib25","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2018.09.009_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/aje\/kwp033","article-title":"Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study","volume":"169","author":"Chen","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.rdc.2018.09.009_bib27","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2018.09.009_bib28","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2018.09.009_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2018.09.009_bib30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2018.09.009_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/art.40583","article-title":"Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib32","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A\u00a0randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib33","doi-asserted-by":"crossref","first-page":"i41","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2018.09.009_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib35","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib37","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2018.09.009_bib38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3899\/jrheum.170387","article-title":"Management of gout in a hospital setting: a lost opportunity","volume":"44","author":"Wright","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7812\/TPP\/15-234","article-title":"A\u00a0pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial","volume":"20","author":"Goldfien","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.rdc.2018.09.009_bib41","unstructured":"Mikuls TR. Improving gout outcomes: the randomized evaluation of an ambulatory care pharmacist-led intervention to optimize urate lowering pathways (RAmP-Up) study. ACR Meeting Abstracts. Available at: http:\/\/acrabstracts.org\/abstract\/improving-gout-outcomes-the-randomized-evaluation-of-an-ambulatory-care-pharmacist-led-intervention-to-optimize-urate-lowering-pathways-ramp-up-study\/."},{"key":"10.1016\/j.rdc.2018.09.009_bib42","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/MLR.0b013e3182a95dd1","article-title":"Successes of a national study of the Chronic Disease Self-Management Program: meeting the triple aim of health care reform","volume":"51","author":"Ory","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.rdc.2018.09.009_bib43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fnhum.2013.00589","article-title":"Making long-term memories in minutes: a spaced learning pattern from memory research in education","volume":"7","author":"Kelley","year":"2013","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.rdc.2018.09.009_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/RHU.0b013e318228b4e2","article-title":"Development and evaluation of a survey of gout patients concerning their knowledge about gout","volume":"17","author":"Zhang","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib45","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A\u00a0randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2018.09.009_bib46","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2018.09.009_bib47","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2018.09.009_bib48","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","article-title":"Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study","volume":"57","author":"Shiramoto","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:08Z","timestamp":1760181368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0889857X18300887"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.09.009","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Challenges of Approaching and Managing Gout","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}